ANDERA PARTNERS
An institutional investment manager in PARIS. Its Form 13F for the quarter ended Jun 30, 2026, filed Jul 22, 2026. SEC CIK 1757283.
- Reported value$206.5m
- Positions8
Holdings: 8 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Kestra Med Technologies Ltd | SHS | G52441105 | 69.4 | 33.6% | 2,728,679 | Added+33,487 | |
| Mineralys Therapeutics IncMLYS | COM | 603170101 | 42.9 | 20.8% | 1,591,917 | Unchanged | |
| Avalyn Pharmaceuticals IncAVLN | COM SHS | 05348Y105 | 30.6 | 14.8% | 929,824 | New+929,824 | |
| Agomab Therapeutics NVAGMB | SPONSORED ADS | 00860C102 | 20.0 | 9.7% | 1,538,702 | Unchanged | |
| Evommune IncEVMN | COM SHS | 30054Y107 | 18.5 | 9.0% | 1,391,990 | Reduced−505,372 | |
| Inventiva SAIVA | ADS | 46124U107 | 13.7 | 6.7% | 3,633,181 | Added+1,815,000 | |
| Abivax SAABVX | SPONSORED ADS | 00370M103 | 10.4 | 5.0% | 78,125 | Unchanged | |
| Nyxoah S a | SHS | B6S7WD106 | 0.9 | 0.4% | 522,057 | Unchanged |
Source: SEC EDGAR, Form 13F-HR, accession 0001757283-26-000015 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.